Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil
Abstract Background Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10-20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less. Main text New targeted therapies such as anti-PD-L1 a...
Saved in:
Main Authors: | Kátia Ramos Moreira Leite (Author), Carlos Henrique Barrios (Author), Antônio Carlos Buzaid (Author), Débora Gagliato (Author), Helenice Gobbi (Author), Fernando Soares (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapy using PD‑1/PDL-1 inhibitors in triple‑negative breast cancer: a systematic review
by: Dione Tavares, et al.
Published: (2021) -
PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell
by: Hualian Zha, et al.
Published: (2022) -
Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
by: Yihang Qi, et al.
Published: (2022) -
Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer
by: Hsuan‐Chen Liu, et al.
Published: (2023) -
Efficacy and Safety of PD-1/PD-L1 Inhibitors in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
by: Zhen-Yu Li, et al.
Published: (2023)